In a recent filing with the Securities and Exchange Commission (SEC), genetics company Illumina revealed that it is partnering with the UK government to sequence 100,000 genomes by 2017. This initiative is focused on gathering data on patients with cancer and rare diseases, and will help researchers better understand the genetic component of human illnesses. While the final budget hasn't been settled on quite yet, it could end up costing UK taxpayers upwards of $200,000,000 just to sequence the patients' DNA.